{"DataElement":{"publicId":"5607587","version":"1","preferredName":"Glioblastoma iRANO Criteria Actual Progression Date","preferredDefinition":"Date of disease progression response status based on iRANO criteria for Glioblastoma.","longName":"GBM_IRANO_ACTL_PD_DT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5607442","version":"1","preferredName":"Glioblastoma Immunotherapy Response Assessment in Neuro-Oncology Criteria Actual Disease Progression","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)_Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC)._Existing in fact; real._The worsening of a disease over time.","longName":"3049870v1.0:5607440v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3049870","version":"1","preferredName":"Glioblastoma","preferredDefinition":"A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.","longName":"C3058","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8EB8-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5607440","version":"1","preferredName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria Actual Disease Progression","preferredDefinition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC). :Existing in fact; real.:The worsening of a disease over time.","longName":"C131131:C25274:C17747","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria","conceptCode":"C131131","definition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Actual","conceptCode":"C25274","definition":"Existing in fact; real.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D100-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D111-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2016-12-30","changeDescription":"Created for GBM Pembro HSPPC study in C3D as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"iRANO Date of actual progress","type":"Preferred Question Text","description":"iRANO Date of actual progression","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"440643B5-309D-324D-E053-F662850A781B","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2016-12-30","changeDescription":"Created for GBM Pembro HSPPC protocol as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}